Blue Jet Healthcare Limited Earnings Summary — Q1 FY2027
Blue Jet Healthcare Reports Sequential Growth in Profits Amidst Successful ₹8,000 Million QIP
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 3 consecutive quarters.
- Revenue of ₹235 Cr is 31.1% lower year-on-year.
- Revenue has compounded at 16.4% annualised over the last 10 quarters.
- Net profit of ₹64 Cr is 41.6% below the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at 36.2% annualised across the period.
- Operating margin stands at 30.4% in Q4 FY2026.
- Operating margin compressed by 1074 bps year-on-year.
- Over the last two years operating margin has expanded by 152 bps.
- PBT margin is 37.1%.
- Expenses grew -18.5% against revenue growth of -31.1%.
- Operating profit of ₹71 Cr is 49.1% lower year-on-year.
- Operating leverage has been under pressure recently.
- 3 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 54/100 (Moderate) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 235 | 192 | 165 | 355 | 340 | 318 | 208 | 163 | 184 | 167 |
| Expenses | Improving | 163 | 146 | 111 | 234 | 200 | 194 | 139 | 119 | 131 | 112 |
| Operating Profit | Improving | 71 | 47 | 55 | 121 | 140 | 124 | 69 | 44 | 53 | 55 |
| Operating Margin | Stable | 30.4% | 24.4% | 33.2% | 34.1% | 41.1% | 39.0% | 33.4% | 27.2% | 28.9% | 32.7% |
| Other Income | Improving | 23 | 13 | 24 | 8 | 12 | 13 | 12 | 9 | 9 | -3 |
| Interest | Volatile | 1 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | Stable | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 3 | 8 | 8 |
| Profit Before Tax | Improving | 87 | 54 | 69 | 123 | 147 | 132 | 77 | 49 | 54 | 44 |
| Tax | Improving | 23 | 14 | 17 | 32 | 37 | 34 | 19 | 12 | 15 | 12 |
| Net Profit | Improving | 64 | 40 | 52 | 91 | 110 | 99 | 58 | 38 | 40 | 32 |
| Net Margin | Improving | 27.4% | 20.9% | 31.5% | 25.7% | 32.3% | 31.1% | 28.0% | 23.2% | 21.6% | 19.3% |
Key Takeaways
- Revenue for Q1 FY2027 increased 24.9% sequentially to ₹2,931.13 million, though it remains down 17.4% compared to the same period last year.
- Net Profit showed strong sequential recovery, growing 21.6% QoQ to ₹782.64 million.
- The company successfully completed a Qualified Institutional Placement (QIP) post-quarter end, raising ₹8,000 million by issuing 15.8 million shares at ₹506 each.
- Board approved the re-appointment of Mr. Akshay B Arora as Executive Chairman and Mr. Shiven Akshay Arora as Managing Director for 5-year terms starting April 2027.
- Cost of materials consumed rose significantly to ₹1,788.78 million, though partially offset by an increase in inventory valuation of ₹417.67 million.
- A dividend of ₹1.2 per share (@60%) was confirmed for FY2025-26, with a record date set for September 14, 2026.
Management Guidance
Management is focusing on organic and inorganic growth following the ₹800 crore capital raise via QIP. The strategic focus remains on 'niche and deep' market segments within Contrast Media and Pharma Intermediates.
Sentiment Shift
Improving
While YoY comparisons are still negative due to a high base and past cyclicality, sequential metrics show a significant rebound in both top-line and bottom-line performance.
Outlook
The outlook is positive regarding capacity expansion following the QIP, though the company must navigate high customer concentration and significant inventory carrying costs.
From the Annual Report (Key Quotes)
“The Company allotted 1,58,10,276 equity shares... aggregating to ₹ 8,000.00 million, pursuant to Qualified Institutional Placement (QIP).”
“The Board of Directors... has approved the re-appointment of Mr. Akshay B Arora as the Whole Time Director and Executive Chairman for a further period of five years.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Blue Jet Healthcare Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.